Invivyd Inc (IVVD) Stock Price, Quote & News

Company Profile

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 819 0080

Website: www.invivyd.com

Address:

209 Church Street, New Haven, United States

Mikeabdurakm Jul. 20 at 11:37 PM

$IVVD this will go up if phase 3 is good. it has strong pipeline which uses similar science so if this phase three is successful the whole entire pipeline will likely be successful cause uses similar science.

0 · Reply

Paulfrench Jul. 20 at 8:10 PM

$IVVD I know it always stings a bit to see a red candle like that, but keep in mind that it’s "potentially" good news—if we want to see the price head back up, this is a necessary step. Now, we need a bullish VSA divergence fairly soon to establish the support level that will fuel our rebound and confirm the bullish divergence on the RSI... hang in there, folks! 🫡☺️

1 · Reply

Rynr Jul. 20 at 7:12 PM

$IVVD Cash ~200m & 202 mcap bull shit

1 · Reply

alexx013 Jul. 20 at 3:35 PM

$IVVD added @ .71

0 · Reply

daybaron Jul. 20 at 2:49 PM

$IVVD how bad can things be when you decide to start dumping at $.70

1 · Reply

daybaron Jul. 20 at 2:47 PM

$IVVD yeah someone knows something and they are probably related to the brokerage firm giving the $10 price target

1 · Reply

BioGem Jul. 17 at 11:59 PM

$IVVD I built a small position here. Many positives: -Previous data has been excellent so far = chance of success almost certain. -A significant number or patients prefer it over vaccinations. -Minimal competition in the field ex-vaccinations. -Several prestigious biotech funds have invested = strong due diligence. -Study fully enrolled with high number of patients for high statistical power. -Cash burn will significantly drop this quarter as phase 3 concludes. -Analysts price targets are much higher than current.

2 · Reply

student56 Jul. 17 at 11:18 PM

$IVVD holding

0 · Reply

billsmall Jul. 17 at 9:38 PM

$IVVD I'd feel better if it was up during market hours when the insts were trading vs after hours when a few po folks thru rent money at it. ugh. Aug 13th is est earnings date, that date scares me a bit to be honest.

0 · Reply

Rynr Jul. 17 at 5:53 PM

$IVVD cooked

0 · Reply

Invivyd announces notice of termination for Pemgarda Emergency Use Authorization

Jul 6, 2026, 7:01 AM EDT - 14 days ago

Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Jul 2, 2026, 7:01 AM EDT - 18 days ago

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 29, 2026, 7:00 AM EDT - 21 days ago

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

NBP

2026-06-16T11:37:10.000Z - 4 weeks ago

Invivyd completes enrollment of LIBERTY clinical trial

Jun 16, 2026, 7:01 AM EDT - 4 weeks ago

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Jun 9, 2026, 7:01 AM EDT - 5 weeks ago

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Jun 8, 2026, 10:00 AM EDT - 6 weeks ago

Invivyd Transcript: H.C. Wainwright “HCW @ Home” Series

Jun 3, 2026, 4:55 PM EDT - 6 weeks ago

Invivyd Transcript: Jefferies Global Healthcare Conference 2026

2026-06-01T11:06:59.000Z - 7 weeks ago

Invivyd completes enrollment in DECLARATION trial

Jun 1, 2026, 7:01 AM EDT - 7 weeks ago

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

May 27, 2026, 7:01 AM EDT - 7 weeks ago

Invivyd to Participate in Upcoming Investor Events

2026-05-19T19:50:10.000Z - 2 months ago

Invivyd management to meet with BTIG

May 19, 2026, 8:30 AM EDT - 2 months ago

Invivyd Transcript: AGM 2026

2026-05-14T19:05:42.000Z - 2 months ago

Invivyd post earnings selloff overdone, says H.C. Wainwright

May 14, 2026, 8:30 AM EDT - 2 months ago

Invivyd Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Invivyd Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Invivyd Slides: Q1 2026

May 14, 2026, 8:30 AM EDT - 2 months ago

Invivyd Quarterly report: Q1 2026

May 14, 2026, 7:01 AM EDT - 2 months ago

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 11, 2026, 7:01 AM EDT - 2 months ago

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

May 7, 2026, 7:01 AM EDT - 2 months ago

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

2026-04-20T11:28:23.000Z - 3 months ago

Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit

Apr 20, 2026, 7:01 AM EDT - 3 months ago

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

2026-04-09T13:34:05.000Z - 3 months ago

Invivyd provides update on Phase 3 DECLARATION study of VYD2311

2026-04-09T13:33:36.000Z - 3 months ago

Invivyd announces discovery, advancement of measles antibody candidate VMS063

Apr 9, 2026, 8:30 AM EDT - 3 months ago

Invivyd Transcript: Study update

Apr 9, 2026, 8:30 AM EDT - 3 months ago

Invivyd Press release: Study update

Apr 9, 2026, 8:30 AM EDT - 3 months ago

Invivyd Slides: Study update

Apr 9, 2026, 7:01 AM EDT - 3 months ago

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Invivyd Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

Invivyd Proxy statement: Proxy filing

Mar 30, 2026, 4:05 PM EDT - 4 months ago

Invivyd Announces Presentation at the World Vaccine Congress Washington

Mar 5, 2026, 8:30 AM EST - 4 months ago

Invivyd Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Invivyd Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Invivyd Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Invivyd Slides: Q4 2025

2026-03-05T12:20:54.000Z - 4 months ago

Invivyd reports cash, cash equivalents of $226.7M as of December 31

2026-03-05T12:20:37.000Z - 4 months ago

Invivyd appoints Michael Mina as CMO

2026-03-05T12:13:36.000Z - 4 months ago

Invivyd reports FY25 EPS (30c) vs. ($1.43) last year

Mar 5, 2026, 7:03 AM EST - 4 months ago

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Mar 5, 2026, 7:01 AM EST - 4 months ago

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Mar 2, 2026, 4:10 PM EST - 5 months ago

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

2026-02-24T12:48:12.000Z - 5 months ago

Invivyd announces peer-reviewed publication using CANOPY trial data

Feb 24, 2026, 7:01 AM EST - 5 months ago

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

2026-02-18T17:40:26.000Z - 5 months ago

Invivyd management to meet virtually with BTIG

2026-02-03T12:05:43.000Z - 5 months ago

Invivyd aligns with FDA on LIBERTY Phase 3 trial of VYD2311

Feb 3, 2026, 7:01 AM EST - 5 months ago

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

2026-01-22T12:16:53.000Z - 6 months ago

Invivyd announces partnership with ski champion Lindsey Vonn

2026-01-20T12:11:41.000Z - 6 months ago

Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

Jan 20, 2026, 7:01 AM EST - 6 months ago

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Jan 8, 2026, 7:01 AM EST - 6 months ago

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Jan 8, 2026, 7:00 AM EST - 6 months ago

Invivyd Slides: Corporate Presentation

Dec 23, 2025, 7:05 AM EST - 7 months ago

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 23, 2025, 7:01 AM EST - 7 months ago

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Dec 19, 2025, 7:00 AM EST - 7 months ago

Invivyd Registration statement: Registration Filing

Dec 2, 2025, 2:35 PM EST - 8 months ago

Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:01 AM EST - 8 months ago

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 7:01 AM EST - 8 months ago

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Nov 17, 2025, 10:40 PM EST - 8 months ago

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 17, 2025, 4:01 PM EST - 8 months ago

Invivyd Announces Proposed Public Offering of Common Stock

Nov 6, 2025, 8:30 AM EST - 9 months ago

Invivyd Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Invivyd Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Invivyd Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Invivyd Slides: Q3 2025

Nov 6, 2025, 7:01 AM EST - 9 months ago

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 3, 2025, 4:01 PM EST - 9 months ago

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Invivyd Transcript: Study Update

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Invivyd Press release: Study Update

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Invivyd Slides: Study Update

Oct 28, 2025, 7:01 AM EDT - 9 months ago

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 6, 2025, 7:01 AM EDT - 10 months ago

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Oct 2, 2025, 8:00 AM EDT - 10 months ago

Invivyd Registration statement: Registration Filing

Sep 24, 2025, 4:01 PM EDT - 10 months ago

Invivyd Appoints Paul B. Bolno, M.D.

Sep 17, 2025, 7:01 AM EDT - 10 months ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 8, 2025, 12:00 PM EDT - 11 months ago

Invivyd Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:01 AM EDT - 11 months ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Sep 3, 2025, 2:10 PM EDT - 11 months ago

Invivyd Transcript: Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:01 AM EDT - 11 months ago

Invivyd to Participate in Upcoming Investor Conferences

Aug 22, 2025, 12:00 PM EDT - 11 months ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 20, 2025, 11:58 PM EDT - 11 months ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 18, 2025, 4:32 PM EDT - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 14, 2025, 4:49 PM EDT - 1 year ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:47 PM EDT - 1 year ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Aug 14, 2025, 9:30 AM EDT - 1 year ago

Invivyd Quarterly report: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 1 year ago

Invivyd Earnings release: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 1 year ago

Invivyd Slides: Q2 2025

Jul 23, 2025, 7:01 AM EDT - 1 year ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 21, 2025, 7:05 AM EDT - 1 year ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 2, 2025, 7:01 AM EDT - 1 year ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jun 26, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

May 27, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 23, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 21, 2025, 9:30 AM EDT - 1 year ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 20, 2025, 11:00 AM EDT - 1 year ago

Invivyd Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Earnings release: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Invivyd Slides: Q1 2025

May 15, 2025, 7:01 AM EDT - 1 year ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 7:01 AM EDT - 1 year ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 13, 2025, 7:01 AM EDT - 1 year ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 12, 2025, 7:01 AM EDT - 1 year ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Mikeabdurakm Jul. 20 at 11:37 PM

0 · Reply

Paulfrench Jul. 20 at 8:10 PM

1 · Reply

Rynr Jul. 20 at 7:12 PM

$IVVD Cash ~200m & 202 mcap bull shit

1 · Reply

alexx013 Jul. 20 at 3:35 PM

$IVVD added @ .71

0 · Reply

daybaron Jul. 20 at 2:49 PM

$IVVD how bad can things be when you decide to start dumping at $.70

1 · Reply

daybaron Jul. 20 at 2:47 PM

$IVVD yeah someone knows something and they are probably related to the brokerage firm giving the $10 price target

1 · Reply

BioGem Jul. 17 at 11:59 PM

2 · Reply

student56 Jul. 17 at 11:18 PM

$IVVD holding

0 · Reply

billsmall Jul. 17 at 9:38 PM

0 · Reply

Rynr Jul. 17 at 5:53 PM

$IVVD cooked

0 · Reply

Doom_Gloom_AR Jul. 17 at 1:08 AM

$IVVD I think the Market has this wrong. There was plenty of covid early in declaration and there is some at the end. Efficacy will be above 75%, as such this should hit. 2331 is better then pemb, particularly the new variants circulation. Pretty high pos. If it fails to hit ss it's because there wasn't enough covid in circulation but I think it just makes it. Certainly at these price levels you have lots of upside.

2 · Reply

student56 Jul. 15 at 2:27 PM

$IVVD no volume LOL

1 · Reply

Paulfrench Jul. 15 at 8:49 AM

$IVVD We'll need to keep an eye on the RSI for this stock; in my opinion, it will signal the reversal

1 · Reply

Jack696 Jul. 14 at 8:53 PM

$IVVD can't afford any delays.

0 · Reply

Zackpedia Jul. 13 at 9:43 AM

$IVVD Down to .8 now! You could’ve…

0 · Reply

BioStick123 Jul. 12 at 9:54 PM

$IVVD Cidara was bought for $9BN . Same thing except for COVID instead of Flu… phase 3 readout this fall

2 · Reply

Aawilliam2003 Jul. 11 at 5:10 PM

$IVVD the science guys believe Covid is now 100% resistant to $IVVD antibody

3 · Reply

BioStick123 Jul. 10 at 5:19 PM

$IVVD priced at failure

1 · Reply

alexx013 Jul. 10 at 4:03 PM

$IVVD added @ .77xx

0 · Reply

BioStick123 Jul. 10 at 2:48 PM

$IVVD this is bound to recover ahead of DECLARATION phase 3 readout

0 · Reply

student56 Jul. 9 at 5:09 PM

$IVVD holding more

0 · Reply

Jack696 Jul. 9 at 3:55 PM

$IVVD this one is scary. Will likely get a Nasdaq warning next week.

0 · Reply

Market Cap	218.75M
Revenue (ttm)	53.43M
Net Income (ttm)	-52.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-98.24%
Debt to Equity Ratio	0.00

Volume	2,725,200
Avg Vol	4,785,200
Day's Range	N/A - N/A
Shares Out	294.61M
Stochastic %K	1%
Beta	0.67
Analysts	Strong Sell
Price Target	$10.00